FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine and represents pharmaceutical compositions and oral dosage forms including granules prepared by wet granulation at a great shear force and containing an anhydrous crystalline (2R)-2-phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate and C6-18 alkylsulphate. The invention also consists in methods of treating Parkinson's disease, schizophrenia, cognitive disorder, restless leg syndrome, periodic limb movement disorder, delayed dyskinesia, Huntington disease, hypertension and daytime sleepiness by administering a therapeutically effective amount of the pharmaceutical composition or dosage form into the patient.
EFFECT: controlling the formation of crystalline (2R)-2-phenylcarbonyloxypropyl(2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate mesylate hydrate.
18 cl, 11 ex, 11 tbl, 9 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| LEVODOPA MESYLATE PRODRUG, COMPOSITION THEREOF AND USE | 2006 |
|
RU2429223C2 |
| LEVODOP PRODRUGS, BASED ON THEM COMPOSITIONS AND THEIR APPLICATION | 2005 |
|
RU2365580C2 |
| CARBIDOPA AND L-DOPA PRODRUGS AND USE THEREOF FOR TREATING PARKINSON'S DISEASE | 2015 |
|
RU2743347C2 |
| NOVEL COMPOUND AND ITS APPLICATION IN MEDICINE | 2011 |
|
RU2570900C2 |
| ANTI-RNA VIRAL, INCLUDING ANTI-CORONAVIRUS AGENT - SUBSTITUTED QUINOXALINE, PHARMACEUTICAL COMPOSITION AND APPLICATIONS | 2020 |
|
RU2744429C1 |
| NUCLEOTIDES INCLUDING N-[(S)-1-CYCLOBUTOXYCARBONYL]PHOSPHORAMIDATE FRAGMENT, THEIR ANALOGS AND THEIR APPLICATION | 2017 |
|
RU2659388C1 |
| PHARMACEUTICAL COMPOSITION IN FORM OF SINGLE ORAL DOSE CONTAINING LEVODOPA, CARBIDOPA AND ENTACAPONE, OR SALTS THEREOF | 2009 |
|
RU2519159C2 |
| PROLONGED-RELEASE PHARMACEUTICAL COMPOSITION OF ENTACAPONE OR ITS SALTS | 2009 |
|
RU2540465C2 |
| PHARMACEUTICAL COMPOSITIONS OF ENTACAPONE, LEVODOPA AND CARBIDOPA WITH IMPROVED BIOAVAILABILITY | 2009 |
|
RU2485947C2 |
| (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID | 2016 |
|
RU2726623C2 |
